Name: Matt Osberg
New title: CFO, Inspire Medical Systems
Previous title: CFO, Apogee Enterprises
Inspire Medical Systems has appointed Matt Osberg as CFO, filling a vacancy created when Rick Buchholz left at the end of last year.
The obstructive sleep apnea company revealed Buchholz’s plans and began searching for a replacement in August. Buchholz agreed to continue in a financial advisory role until late February. Osberg is set to start as Inspire’s CFO on Jan. 19.
While Osberg is from Minneapolis, a medtech hub where Inspire is based, he previously worked outside of the industry. Osberg is joining Inspire from Apogee Enterprises, which sells architectural products and services. Earlier in his career, Osberg worked at consumer goods company Helen of Troy and electronics retailer Best Buy.
Inspire CEO Tim Herbert commented on Osberg’s background in a presentation at the 2026 J.P. Morgan Healthcare Conference on Monday. Osberg is “really not a medtech person,” Herbert said. Yet Inspire, which Herbert said “searched the world to find the right individual,” concluded that medtech experience was less important than other attributes.
“We know medtech. We weren’t necessarily focused on a medtech person,” Herbert said. “We wanted somebody who [we] could really bring in and help us go to the next level. So, very exciting from that standpoint.”
Inspire shared news of Osberg’s appointment alongside preliminary unaudited financial results for the fourth quarter of 2025. The company expects fourth-quarter sales of $268.9 million to $269.1 million. The sales range, which reflects approximately 12% growth year over year, is above the consensus Wall Street estimate of $262.2 million, J.P. Morgan analysts said in a note to investors.
The analysts said Inspire’s initial 2026 guidance for just over $1 billion in full-year sales is more important than the fourth-quarter results. The guidance is in line with Wall Street expectations, the analysts said, and provides “the reasonable baseline investors were looking for.” Inspire’s outlook does not factor in possible increased reimbursement, a decision the analysts supported given last year’s “roller coaster.”
